Examining the True Prevalence of Hypercortisolism and Its Impact on Managing Resistant Diabetes

The CATALYST study is discussed by a panel of experts led by Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES.

Key opinion leaders navigate challenges associated with diabetes management.

The expert panel analyze data from the CATALYST trial.

The panel of medical experts discuss the prevalence of hypercortisolism based on the CATALYST trial.

Medical experts discuss the implications of finding hypercortisolism in one-third of patients on three or more hypertension medications, the linkage between hypercortisolism and type 2 diabetes as presented in the ‘Pathologic Mechanisms of Hypercortisolism in Type 2 Diabetes’ session, and how hypercortisolism affects diabetes management, including the importance of addressing it and its consequences for patients with difficult-to-control diabetes.

Medical experts explore why findings from this study are crucial for clinicians managing diabetes, particularly those in primary care settings, and how these insights can impact their approach to patient care.

Key opinion leaders explore the diverse clinical manifestations of hypercortisolism across its spectrum of presentations.

Experts discuss the CATALYST study's evaluation of mifepristone for hypercortisolism patients with hard-to-manage type 2 diabetes, its mechanism of action, suitable patient populations, treatment approaches for those with adrenal tumors, and factors determining surgical candidacy.

Panelists discuss how treating hypercortisolism in patients may have long-term effects on glycemic control and overall health, potentially influencing future standards of care for difficult-to-control Type 2 diabetes, while emphasizing the need for clinicians to carefully manage such patients as ongoing research continues.